This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Oscar Health, Inc. (OSCR) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Oscar Health, Inc. (OSCR) closed the most recent trading day at $16.59, moving +1.22% from the previous trading session.
Is Oscar Health (OSCR) Outperforming Other Finance Stocks This Year?
by Zacks Equity Research
Here is how Oscar Health, Inc. (OSCR) and Palomar (PLMR) have performed compared to their sector so far this year.
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYX
Wall Street Bulls Look Optimistic About Oscar Health (OSCR): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Oscar Health (OSCR) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
5 Low-Leverage Stocks to Buy as Inflation Data Meets Expectation
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may add VITL, TCOM, ATO, STRA & OSCR to your portfolio.
3 Insurance Stocks to Buy as Interest Rates Remain High
by Abhinab Dasgupta
American Coastal (ACIC), Hamilton Insurance (HG) and Oscar Health (OSCR) are three insurance stocks that you can look into as interest rates stay higher for longer.
Oscar Health (OSCR) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Oscar Health (OSCR) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Oscar Health, Inc. (OSCR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Oscar Health (OSCR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fast-paced Momentum Stock Oscar Health (OSCR) Is Still Trading at a Bargain
by Zacks Equity Research
Oscar Health (OSCR) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Oscar Health, Inc. (OSCR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Oscar Health (OSCR) delivered earnings and revenue surprises of 121.43% and 9.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
Don't Overlook These Top Medical Stocks as Q1 Earnings Approach
by Shaun Pruitt
Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Aflac (AFL) Q1 Earnings Beat on Lower Benefits & Expenses
by Zacks Equity Research
Aflac (AFL) estimates improved sales in its Japan business for 2024, buoyed by sales campaigns commencing in the second quarter.
Prudential (PRU) Lags Q1 Earnings Estimates
by Zacks Equity Research
Prudential (PRU) delivered earnings and revenue surprises of -1.27% and 46.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYX
Why Fast-paced Mover Oscar Health, Inc. (OSCR) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Oscar Health, Inc. (OSCR) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Despite Fast-paced Momentum, Oscar Health, Inc. (OSCR) Is Still a Bargain Stock
by Zacks Equity Research
Oscar Health, Inc. (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Oscar Health, Inc. (OSCR) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Oscar Health, Inc. (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Oscar Health, Inc. (OSCR) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Oscar Health, Inc. (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
November Marks Best Month Since 2022: 4 Best Sectors & Stock Picks
by Sanghamitra Saha
November marked an exceptional month for stocks. Interest rate-sensitive sectors and stocks like Udemy (UDMY), Oscar Health (OSCR), Rocky Brands (RCKY) and Landsea Homes (LSEA) outperformed in the month.
Oscar Health, Inc. (OSCR) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Oscar Health, Inc. (OSCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Oscar Health, Inc. (OSCR) Could Rally 59.34%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Oscar Health, Inc. (OSCR) points to a 59.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for October 20th
by Zacks Equity Research
OSCR, IMGN, AFRM, ACVA and SOLO have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2023.